Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAIA Biotechnology, Inc.MAIA · Entity 6919 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAIA Biotechnology, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2036-09-30 | IndirectSee footnote | 38,871 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 38,871 · Balance 38,871 F1: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. F2: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
F2: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 21, 2023 Filed Mar 22, 2023 10:42 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 2,736 | $3.17 | $8,673.12 |
DisclosureSEC source: 0001127602-23-010968 · form4.xml · nonDerivative · entry 2 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 539,070 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.10 to $3.57 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 10:42 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 3,006 | $3.28 | $9,859.68 |
DisclosureSEC source: 0001127602-23-010968 · form4.xml · nonDerivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 536,334 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.18 to $3.345 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 10:25 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 3,582 | $4.03 | $14,435.46 |
DisclosureSEC source: 0001127602-23-009811 · form4.xml · nonDerivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 533,328 F1 · shares: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F2 · shares: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.87 to $4.165, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:30 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 3,076 | $4.20 | $12,919.20 |
DisclosureSEC source: 0001127602-23-009534 · form4.xml · nonDerivative · entry 2 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 529,746 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.06 to $4.25 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 11:30 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 1,961 | $4.23 | $8,295.03 |
DisclosureSEC source: 0001127602-23-009534 · form4.xml · nonDerivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 526,670 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.20 to $4.25 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 11:33 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 4,594 | $4.39 | $20,167.66 |
DisclosureSEC source: 0001127602-23-009205 · form4.xml · nonDerivative · entry 2 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 524,709 F1 · shares: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F3 · shares: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.23 to $4.50 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 11:33 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 2,509 | $4.43 | $11,114.87 |
DisclosureSEC source: 0001127602-23-009205 · form4.xml · nonDerivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 520,115 F1 · shares: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F2 · shares: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.39 to $4.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 11:10 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 23 | $4.41 | $101.43 |
DisclosureSEC source: 0001127602-23-008532 · form4.xml · nonDerivative · entry 2 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 517,606 F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 11:10 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 198 | $4.48 | $887.04 |
DisclosureSEC source: 0001127602-23-008532 · form4.xml · nonDerivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 517,583 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.43 to $4.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 11:38 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 1,619 | $4.48 | $7,253.12 |
DisclosureSEC source: 0001127602-23-007701 · form4.xml · nonDerivative · entry 2 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 517,385 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.43 to $4.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 11:38 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 219 | $4.47 | $978.93 |
DisclosureSEC source: 0001127602-23-007701 · form4.xml · nonDerivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 515,766 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.45 to $4.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| February 22, 2023 Filed Feb 23, 2023 11:42 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 1,073 | $4.48 | $4,807.04 |
DisclosureSEC source: 0001127602-23-006606 · form4.xml · nonDerivative · entry 2 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 515,547 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.41 to $4.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 11:42 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 228 | $4.49 | $1,023.72 |
DisclosureSEC source: 0001127602-23-006606 · form4.xml · nonDerivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 514,474 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.41 to $4.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 11:58 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 75 | $4.25 | $318.75 |
DisclosureSEC source: 0001127602-23-006047 · form4.xml · nonDerivative · entry 2 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 514,246 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 11:58 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 62 | $4.25 | $263.50 |
DisclosureSEC source: 0001127602-23-006047 · form4.xml · nonDerivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 514,171 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| February 15, 2023 Filed Feb 16, 2023 11:46 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 10 | $4.25 | $42.50 |
DisclosureSEC source: 0001127602-23-005440 · form4.xml · nonDerivative · entry 2 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 514,109 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 11:46 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 198 | $4.25 | $841.50 |
DisclosureSEC source: 0001127602-23-005440 · form4.xml · nonDerivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 514,099 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 11:58 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 337 | $4.25 | $1,432.25 |
DisclosureSEC source: 0001127602-23-005031 · form4.xml · nonDerivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 513,901 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.24 to $4.25, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 12:15 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 227 | $4.24 | $962.48 |
DisclosureSEC source: 0001127602-23-002395 · form4.xml · nonDerivative · entry 2 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 513,564 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.18 to $4.25, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 12:15 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 9 | $4.25 | $38.25 |
DisclosureSEC source: 0001127602-23-002395 · form4.xml · nonDerivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 513,337 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 12:42 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 500 | $3.50 | $1,750.00 |
DisclosureSEC source: 0001127602-23-000002 · form4.xml · nonDerivative · entry 2 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 513,328 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 22:50 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 3,807 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0001127602-23-000649 · form4.xml · derivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 3,807 Underlying: Common Stock · 3,807 shares Expires 2032-12-30 F1 · derivative.exercise_date: The stock options, granted on December 30, 2022 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 12:42 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 1,471 | $3.49 | $5,133.79 |
DisclosureSEC source: 0001127602-23-000002 · form4.xml · nonDerivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 512,828 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.46 to $3.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| December 28, 2022 Filed Dec 29, 2022 12:43 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 1,266 | $3.41 | $4,317.06 |
DisclosureSEC source: 0001127602-22-028331 · form4.xml · nonDerivative · entry 2 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 511,357 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.345 to $3.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| December 27, 2022 Filed Dec 29, 2022 12:43 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 604 | $3.38 | $2,041.52 |
DisclosureSEC source: 0001127602-22-028331 · form4.xml · nonDerivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 510,091 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.29 to $3.485 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| December 23, 2022 Filed Dec 27, 2022 13:32 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 981 | $3.45 | $3,384.45 |
DisclosureSEC source: 0001127602-22-028285 · form4.xml · nonDerivative · entry 2 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 509,487 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.35 to $3.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 13:32 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 731 | $3.34 | $2,441.54 |
DisclosureSEC source: 0001127602-22-028285 · form4.xml · nonDerivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 508,506 F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.25 to $3.42, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 13:00 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 399 | $3.43 | $1,368.57 |
DisclosureSEC source: 0001127602-22-028136 · form4.xml · nonDerivative · entry 2 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 507,775 F2 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.30 to $3.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F2 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 13:00 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 4,048 | $3.53 | $14,289.44 |
DisclosureSEC source: 0001127602-22-028136 · form4.xml · nonDerivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 507,376 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.42 to $3.70, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F2 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. F2 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| September 19, 2022 Filed Jan 12, 2026 13:44 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 2,700 | $3.69 | $9,958.68 |
DisclosureSEC source: 0001878313-26-000021 · form4.xml · nonDerivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,424,178 F1 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 22:41 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | OtherCommon Stock | 7,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-027462 · doc4.xml · nonDerivative · entry 2 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 503,328 F3 · kind: In connection with a crossover round with certain investors consisting of sales of common stock, $0.0001 par value per share ("Common Stock") of the Issuer at a price of $9.00 per share, in the event that the price per share of Common Stock sold in the IPO was less than $9.00 per share, the Issuer, on the closing date of the IPO (August 1, 2022), issued to such investors, so long as they continued to hold such shares of Common Stock purchased in the crossover round, that number of additional shares of Common Stock such that the price per share they paid in the crossover round was equal to the per share price in the Issuer's IPO. As the reporting person purchased 9,000 shares at $9.00 per share in the crossover round that the reporting person continued to hold, and the per share price in the IPO was $5.00 per share, accordingly, at the close of the IPO, the Issuer issued to the reporting person an additional 7,200 shares of Common Stock for no additional consideration. F3 · price: In connection with a crossover round with certain investors consisting of sales of common stock, $0.0001 par value per share ("Common Stock") of the Issuer at a price of $9.00 per share, in the event that the price per share of Common Stock sold in the IPO was less than $9.00 per share, the Issuer, on the closing date of the IPO (August 1, 2022), issued to such investors, so long as they continued to hold such shares of Common Stock purchased in the crossover round, that number of additional shares of Common Stock such that the price per share they paid in the crossover round was equal to the per share price in the Issuer's IPO. As the reporting person purchased 9,000 shares at $9.00 per share in the crossover round that the reporting person continued to hold, and the per share price in the IPO was $5.00 per share, accordingly, at the close of the IPO, the Issuer issued to the reporting person an additional 7,200 shares of Common Stock for no additional consideration. F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 22:41 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 200,000 | $5.00 | $1,000,000.00 |
DisclosureSEC source: 0000899243-22-027462 · doc4.xml · nonDerivative · entry 1 Smith Stan · CIK 0001913199 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 496,128 F1 · kind: These shares were purchased in the initial public offering (the "IPO") of MAIA Biotechnology, Inc. (the "Issuer"), which closed on August 1, 2022. F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.